Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases

Brian Poligone, Belen Rubio-Gonzalez, Christiane Querfeld

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Cutaneous T-cell lymphomas (CTCL) are a relatively rare and heterogeneous group of non-Hodgkin lymphomas that typically present in the skin. The majority of patients with CTCL experience pruritus, which can interfere with daily activities, significantly impact quality of life, and is typically uncontrolled by standard anti-itch therapies. Several lymphoma treatments have reported anti-pruritic effects including romidepsin, a potent class 1 selective histone deacetylase inhibitor approved for the treatment of patients with CTCL who have had at least one prior systemic therapy. Here, we describe the cases of four patients with debilitating and refractory pruritus that were resolved with romidepsin. Resolution of pruritus was observed in both clinical responders and nonresponders, and dose modification was used successfully to manage adverse events and for maintenance treatment. The potential for pruritus relief with romidepsin should be considered when treating patients with CTCL.

Original languageEnglish
Article numbere12804
JournalDermatologic Therapy
Volume32
Issue number2
DOIs
StatePublished - 1 Mar 2019
Externally publishedYes

Keywords

  • cutaneous T-cell lymphoma
  • lenalidomide
  • pruritus
  • romidepsin

Fingerprint

Dive into the research topics of 'Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases'. Together they form a unique fingerprint.

Cite this